Celiac Disease Treatment Market Size and Forecast 2026-2035: Key Numbers
The Celiac Disease Treatment market is valued at USD 450.00 Million in 2025 and is projected to reach USD 1.99 Billion by 2035, growing at a 16.0% CAGR, according to Strategic Revenue Insights. That is a 4.4x increase, driven by a maturing clinical pipeline in a field where no drug has been approved yet.
Key Facts at a Glance
- Market size 2025: USD 450.00 Million
- Forecast 2035: USD 1.99 Billion
- CAGR 2026 to 2035: 16.0%
- Largest segment: gluten-free diet support, 58% of treatment
- Fastest growing drug class: vaccines, 24.7% CAGR
- Leading region: North America, about 45%
- Key companies: Takeda, Dr. Falk Pharma, Amgen, Teva, Merck KGaA, AstraZeneca
What Is Driving Celiac Disease Treatment Market Growth?
Clinical pipeline progress is the largest driver, adding about 4.5 percentage points to growth. The unmet need for therapies beyond a strict gluten-free diet adds 3.8 points, rising diagnosis rates from tTG-IgA screening add 3.2 points, and FDA fast-track designations and EMA scientific advice add 2.4 points.
Which Segments Lead the Market?
Gluten-free diet support holds 58% of the market today. Among drug classes, enzyme therapeutics lead with a 34% share, while vaccines are the fastest growing at 24.7%. Retail pharmacies are the largest channel at 41.5%, and online pharmacies grow fastest at 20.4%. Gastroenterology clinics are both the largest and fastest growing end user, with 43% and a 17.2% CAGR.
Which Region Dominates?
North America leads with about 45% of the market. Asia Pacific is the fastest growing region at a 19.2% CAGR as screening and diagnosis expand.
Who Are the Key Players?
Takeda, Dr. Falk Pharma, Amgen, Teva, Merck KGaA and AstraZeneca are among the companies profiled. The top five hold about 40% of the market.
Frequently Asked Questions
How big is the celiac disease treatment market? It is valued at USD 450.00 Million in 2025 and is expected to reach USD 1.99 Billion by 2035.
Is there an approved drug for celiac disease? Not yet. Diet remains the standard of care, which is why pipeline progress is the main growth driver.
Which drug class grows fastest? Vaccines, at a 24.7% CAGR through 2035.
Full Report
The 234-page report (ID 92743) covers market size, segments, regions and competitors from 2025 to 2035. Request a free sample: https://www.strategicrevenueinsights.com/industry/celiac-disease-treatment-market
Source: Strategic Revenue Insights Inc.

Comments
Post a Comment